Reduced P3a amplitudes in antipsychotic naïve first-episode psychosis patients and individuals at clinical high-risk for psychosis
Por:
Mondragón-Maya A., Solís-Vivanco R., León-Ortiz P., Rodríguez-Agudelo Y., Yanez-Tellez, G, Bernal-Hernández J., Cadenhead K.S., de la Fuente-Sandoval C.
Publicada:
1 jun 2013
Resumen:
Event related potentials (ERP) associated with early sensory information processing have been proposed as possible vulnerability markers for psychosis. Compared to other ERPs reported in schizophrenia research, like Mismatch Negativity (MMN), little is known about P3a, an ERP related to novelty detection. The aim of this study was to analyze the MMN-P3a complex in 20 antipsychotic naïve first-episode psychosis patients (FEP), 23 antipsychotic naïve individuals at clinical high-risk for psychosis (CHR) and 24 healthy controls. The MMN-P3a amplitudes and latencies were obtained during a passive auditory mismatch frequency deviant ERP paradigm and analyzed in frontal and central scalp regions. There were no significant differences in MMN amplitude between groups. There was a significant group difference in P3a due to reduced amplitude (F[2,64] = 3.7, p = 0.03) in both CHR and FEP groups (Mean difference (MD) = 0.39, p = 0.04 and MD = 0.49, p = 0.02, respectively) compared to the control group and this effect was most prominent on the right side (Group × laterality effect: MD = 0.57, p < 0.01 and MD = 0.58, p < 0.01, respectively). No significant differences were observed for MMN or P3a latencies between groups. Although a P3a decrement in chronic schizophrenia and FEP has been previously reported, our results suggest that this novelty detection impairment is present even in pre-psychosis stages in antipsychotic naïve subjects. This study supports the evidence that P3a could represent a neurophysiological vulnerability marker for the development of psychosis. © 2013 Elsevier Ltd.
Filiaciones:
Mondragón-Maya A.:
Neuropsychology Department, Instituto Nacional de Neurología y Neurocirugía, Insurgentes Sur 3877, La Fama, Tlalpan, 14269, Mexico City, Mexico
Solís-Vivanco R.:
Neuropsychology Department, Instituto Nacional de Neurología y Neurocirugía, Insurgentes Sur 3877, La Fama, Tlalpan, 14269, Mexico City, Mexico
León-Ortiz P.:
Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologia Y Neurocirugia, Mexico City, Mexico
Rodríguez-Agudelo Y.:
Neuropsychology Department, Instituto Nacional de Neurología y Neurocirugía, Insurgentes Sur 3877, La Fama, Tlalpan, 14269, Mexico City, Mexico
Yanez-Tellez, G:
Univ Nacl Autonoma Mexico, Fac Estudios Super Iztacala, Los Reyes Iztacala, Tlalnepantla, Mexico
Bernal-Hernández J.:
Univ Nacl Autonoma Mexico, Fac Estudios Super Iztacala, Los Reyes Iztacala, Tlalnepantla, Mexico
Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Av. de los Barrios 1, Los Reyes Iztacala, Tlalnepantla, Mexico
Cadenhead K.S.:
Department of Psychiatry, University of California, San Diego, La Jolla, United States
San Diego Veterans Affairs Medical Center, 9500 Gilman Drive, La Jolla, CA 92093-0603, United States
de la Fuente-Sandoval C.:
Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologia Y Neurocirugia, Mexico City, Mexico
Neuropsychiatry Department, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
|